Head to Head Contrast: Entera Bio (NASDAQ:ENTX) and Vericel (NASDAQ:VCEL)

Entera Bio (NASDAQ:ENTX) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Entera Bio and Vericel, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	0	0	1	0	3.00
Vericel	0	0	7	0	3.00

Entera Bio presently has a consensus target price of $10.00, indicating a potential upside of 521.12%. Vericel has a consensus target price of $51.33, indicating a potential upside of 1.61%. Given Entera Bio’s higher probable upside, analysts clearly believe Entera Bio is more favorable than Vericel.

Profitability

This table compares Entera Bio and Vericel’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-103.40%	-85.00%
Vericel	0.22%	0.21%	0.13%

Volatility & Risk

Entera Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Insider and Institutional Ownership

14.1% of Entera Bio shares are owned by institutional investors. 10.9% of Entera Bio shares are owned by insiders. Comparatively, 5.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Entera Bio and Vericel’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$130,000.00	443.12	-$8.89 million	($0.28)	-5.75
Vericel	$197.52 million	12.43	-$3.18 million	($0.01)	-5,046.95

Vericel has higher revenue and earnings than Entera Bio. Vericel is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Vericel beats Entera Bio on 8 of the 13 factors compared between the two stocks.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.